Novel therapy for renal anemia using human iPS cells
| Project/Area Number |
18K08246
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53040:Nephrology-related
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 再生医学 / iPS細胞 / 移植・再生医療 / エリスロポエチン / 腎性貧血 / 薬効評価 / 細胞療法 / レチノイン酸 |
|---|
| Outline of Final Research Achievements |
Erythropoietin dysregulation is a hallmark of renal anemia. Although recombinant erythropoietin is beneficial and safe, more physiological therapies are required. We developed a differentiation protocol for erythropoietin-producing cells from human iPS cells. These cells produced and secreted functional erythropoietin protein. In addition, transplantation of these cells into a mouse model improved renal anemia. From the perspective of basic research, these cells may be a useful tool for investigating the molecular mechanisms of erythropoietin production and secretion. From the perspective of clinical research, these results may provide a physiological therapeutic agent for renal anemia.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果は、腎性貧血の治療に対する安価でより生理的な管理を可能とする医療技術の向上に加え、貧血に対する新規治療法の開発による本邦の医薬産業界の活性化をもたらすものである。これまでヒトiPS細胞を用いた再生医療の試みがなされているが、エリスロポエチン産生細胞に関しては我々以外の報告は存在せず、本研究は全く新規で独自のものである。患者自身の体細胞から樹立され、ほぼ無限に増殖する能力を有する多能性幹細胞であるiPS細胞を用いることで、免疫抑制の必要ないエリスロポエチン産生細胞を大量に作製することも可能であり、今後も需要の増す腎性貧血治療に対して有効な手段になりうる。
|
Report
(4 results)
Research Products
(20 results)
-
-
-
-
-
[Journal Article] Effects of an SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.2018
Author(s)
Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori H, Nishiyama A.
-
Journal Title
J. Pharmacol. Sci.
Volume: 137
Issue: 2
Pages: 220-223
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
[Presentation] Human pluripotent stem cell-derived erythropoietin-producing cells improve renal anemia in mice2018
Author(s)
Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae S, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito M, Nakahata T, Nishiyama A, Osafune K
Organizer
ISSCR 2018 Annual Meeting
Related Report
Int'l Joint Research
-
-
[Presentation] iPS細胞由来エリスロポエチン産生細胞を用いた腎性貧血に対する細胞療法開発2018
Author(s)
人見浩史, 笠原朋子, 片桐直子, 保科あずさ, 前伸一, 小髙真希, 豊原敬文, Asadur Rahman, 中野大介, 丹羽明, 斎藤潤, 中畑龍俊, 西山成, 長船健二
Organizer
第61回日本腎臓学会学術総会
Related Report
-
-
-
